All News

RheumNow Podcast square

ACR Award Winners (10.21.2022)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlighted discussion of implantable stimulators, urine proteomics and gut-immune responses to Prevotella in RA.

Read Article
covid.corona

Vaccination Cut Long COVID Risk for Rheum Patients

d MedPage Today

Patients with rheumatologic conditions who developed breakthrough COVID-19 infection after vaccination were less likely to suffer long-term symptoms than unvaccinated but otherwise similar patients, researchers said.

Read Article
Dr. Kent Kwoh and Researchers at the University of Arizona Arthritis Center have been awarded a $3.4 million grant from the National Institutes of Health to undertake a study that seeks to identify determinants of rapid knee deterioration in OA https://t.co/K9wxRzmVnw https://t.co/nM7ByxKikB

Links:

Dr. John Cush RheumNow ( View Tweet)
Anakinra in Pericarditis: A Systematic Review (comprehensive, full read) -Options include steroids, colchicine, NSAIDs, pleuropericardial window, IL-1 inhibitors. ANAKINRA - 11 studies, 259 pts, all showing significant rapid resolution. https://t.co/mEkaa7Yjt1 https://t.co/BaMYHiG5Pb

Links:

Dr. John Cush RheumNow ( View Tweet)
Highlights from the @ACRheum Kawasaki Disease Guidelines 🥇IVIG is mainstay therapy (2 g/kg) 👶🏼 Use ASA in acute KD 🗣Refractory cases may require steroids or additional immunosuppression 🫀Get echos on all patients to assess for coronary aneurysms

Catherine Sims, MD DrCassySims ( View Tweet)

Tawanese claims analysis of 10,857 RA pts shows lower CVA rates when taking Celebrex (5.95% vs 9.72% not taking) or Etoricoxib (2.69% vs 8.51% not taking). Both Celebrex/Etoricoxib significantly reduced stroke risk p < 0.001 https://t.co/6idrH9g0LJ https://t.co/d80bEtsP7k

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approves RINVOQ (upadacitinib) for the treatment of Active Non-Radiographic Axial Spondyloarthritis https://t.co/DMuQFjFdrf https://t.co/zLsniZ2zOg

Links:

Dr. John Cush RheumNow ( View Tweet)
Health Canada has approved EVUSHELD to treat COVID-19 in immunocompromised patients (it was previously approved to prevent COVID) https://t.co/ePgd4DjTka https://t.co/whgSM3ce7Q

Links:

Dr. John Cush RheumNow ( View Tweet)
Follow us for real time coverage #ACR2022 https://t.co/5CBdiKWdKM
Dr. John Cush RheumNow ( View Tweet)

“If you torture the data long enough it will confess” -Ronald Coase (economist) https://t.co/ZGivhUWLZW

Dr. John Cush RheumNow ( View Tweet)

How do Pts check Temps? Paired oral & temporal temps in 2031 Blacks & 2344 Whites: / whites showed no diff (36.97 vs 36.95°C), but signif diff in blacks (36.98 vs 37.05). Fever seen in 10.2-10.8% Whites, but 10.1% (temporal), 13.2% (oral) in Blacks https://t.co/D4XowfsYXD https://t.co/LmvEnAVGbr

Links:

Dr. John Cush RheumNow ( View Tweet)
Pregnancy Outcomes with Belimumab A study of SLE pregnancies exposed to belimumab (BEL) shows and expected rate of pregnancy loss but a variable rate of birth defects. https://t.co/cXm58iSmVc https://t.co/Hdg6Qg1uHE

Links:

Dr. John Cush RheumNow ( View Tweet)
Prevotella Immune Response in Both Pre-Clinical & Established RA In a recent analysis published in Arthritis & Rheumatology, people at risk for RA and those with the disease had elevated blood levels of antibodies against a Prevotella copri (Pc). https://t.co/6zArTx4XlM https://t.co/9UIk2OOhXq

Links:

Dr. John Cush RheumNow ( View Tweet)
Difficult to treat RA (D2T-RA) study of 48 D2T-145 non-D2T-RA pts. D2T-RA was predicted by Not starting MTX w/in 3 mos (17% vs 33% non-D2T-RA;p= 0.011) &being on steroids > 6 mos (71% vs 34%, p< 0.001). https://t.co/Ugbr7z7mia https://t.co/TCU7wSfMrS

Links:

Dr. John Cush RheumNow ( View Tweet)
mRNA COVID vaccine study from Vaccine Safety Datalink shows risk of myocarditis/pericarditis 0-7d post Vax (ages 5-39) is ~1/200K doses (1st dose), 1/ 30K(2nd dose), 1/50K (1st booster); w/ higher risk in adolescent males https://t.co/J1u038qxB7 https://t.co/vEUNbOvEQf

Links:

Dr. John Cush RheumNow ( View Tweet)

Anakinra in Pericarditis: A Systematic Review (comprehensive, full read) -Options include steroids, colchicine, NSAIDs, pleuropericardial window, IL-1 inhibitors. ANAKINRA - 11 studies, 259 pts, all showing significant rapid resolution. https://t.co/rcnTPkDTjq https://t.co/RbW1fPSjfU

Links:

Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine Dosing and SLE Flares A cohort study examining HCQ dosing in patients with SLE suggests that HCQ doses of 5 mg/kg per day or less, was associated with a higher risk of lupus flares, including moderate or severe lupus flares. https://t.co/UeIZ70zRnt https://t.co/tGrBSydvKB

Links:

Dr. John Cush RheumNow ( View Tweet)
Top Tweet of September: Gout: diagnosis and management—summary of NICE guidance https://t.co/CWg4otNBVv https://t.co/wRcjnC59eL

Links:

Dr. John Cush RheumNow ( View Tweet)
Long COVID study (54 studies, 2 databases, 1.2 million pts) showed at least 1 in 3 reported Long COVID Sx clusters (fatigue, bodily pain, mood swings, cognitive or resp Sxs), more common in women <20 yrs, w/ duration 9 mos in Hosp pts https://t.co/vuJrpWizzr https://t.co/e58J8rctEC

Links:

Dr. John Cush RheumNow ( View Tweet)
Spinal cord stimulation is a $2-3billion market, despite limited efficacy. A placebo controlled trial of spinal cord burst stimulation, in 50 pts w/ chr radicular pain after lumbar surgery, showed no significant benefit in back pain–related disability. https://t.co/aRN5sRbqFx https://t.co/A37LWaYEGw

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×